ViiV Healthcare, a subsidiary of GlaxoSmithKline’s focusing on HIV, has reported today, before trading started in Europe, results from the Phase III Atlas clinical trial, enrolling 618 patients with HIV, treated with a cabotegravir-rilpivirine injected treatment for 48 weeks. The results show that GSK’s two-drug regime has similar efficacy to conventional three-drug treatments, yet these are more harmful to the organism. Other positive results were announced in July as a study conducted with GSK’s oral two-drug regimen of dolutegravir and lamivudine delivered positive safety and toxicity data. The treatment is already on the market and is expected to generate at least GBP5.2bn before 2022. Thanks to all these results, GSK expects to achieve a leading position in the HIV treatments market, worth at least $20bn, whose main player is probably California-based Gilead.